GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sci Pharmtech Inc (TPE:4119) » Definitions » Cyclically Adjusted PS Ratio

Sci Pharmtech (TPE:4119) Cyclically Adjusted PS Ratio : 3.67 (As of Jun. 02, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Sci Pharmtech Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Sci Pharmtech's current share price is NT$66.40. Sci Pharmtech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was NT$18.11. Sci Pharmtech's Cyclically Adjusted PS Ratio for today is 3.67.

The historical rank and industry rank for Sci Pharmtech's Cyclically Adjusted PS Ratio or its related term are showing as below:

TPE:4119' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.34   Med: 4.76   Max: 6.14
Current: 3.76

During the past years, Sci Pharmtech's highest Cyclically Adjusted PS Ratio was 6.14. The lowest was 3.34. And the median was 4.76.

TPE:4119's Cyclically Adjusted PS Ratio is ranked worse than
70.6% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs TPE:4119: 3.76

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sci Pharmtech's adjusted revenue per share data for the three months ended in Mar. 2025 was NT$3.006. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$18.11 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sci Pharmtech Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sci Pharmtech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sci Pharmtech Cyclically Adjusted PS Ratio Chart

Sci Pharmtech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.42 4.00 4.66 5.33 5.00

Sci Pharmtech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 4.96 4.94 5.00 4.29

Competitive Comparison of Sci Pharmtech's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sci Pharmtech's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sci Pharmtech's Cyclically Adjusted PS Ratio falls into.


;
;

Sci Pharmtech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sci Pharmtech's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=66.40/18.11
=3.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sci Pharmtech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Sci Pharmtech's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.006/134.9266*134.9266
=3.006

Current CPI (Mar. 2025) = 134.9266.

Sci Pharmtech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 5.387 100.684 7.219
201509 4.064 100.392 5.462
201512 3.190 99.792 4.313
201603 5.905 100.470 7.930
201606 4.783 101.688 6.346
201609 4.344 101.861 5.754
201612 2.374 101.863 3.145
201703 3.006 102.862 3.943
201706 2.609 103.349 3.406
201709 3.248 104.136 4.208
201712 3.019 104.011 3.916
201803 3.898 105.290 4.995
201806 4.850 106.317 6.155
201809 4.747 106.507 6.014
201812 4.261 105.998 5.424
201903 5.492 107.251 6.909
201906 5.504 108.070 6.872
201909 5.729 108.329 7.136
201912 4.725 108.420 5.880
202003 7.132 108.902 8.836
202006 6.655 108.767 8.256
202009 6.195 109.815 7.612
202012 4.565 109.897 5.605
202103 2.954 111.754 3.567
202106 1.648 114.631 1.940
202109 2.070 115.734 2.413
202112 1.246 117.630 1.429
202203 1.723 121.301 1.917
202206 1.481 125.017 1.598
202209 2.776 125.227 2.991
202212 2.199 125.222 2.369
202303 3.177 127.348 3.366
202306 2.919 128.729 3.060
202309 2.405 129.860 2.499
202312 2.529 129.419 2.637
202403 2.587 131.776 2.649
202406 3.284 132.554 3.343
202409 3.498 133.029 3.548
202412 3.347 133.157 3.391
202503 3.006 134.927 3.006

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sci Pharmtech  (TPE:4119) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sci Pharmtech Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sci Pharmtech's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sci Pharmtech Business Description

Traded in Other Exchanges
N/A
Address
No.61, Lane 309, Haihu North Road, Luzhu District, Taoyuan, TWN, 33856
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, China, Switzerland, Spain, and others.

Sci Pharmtech Headlines

No Headlines